Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2014. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs) regarding their personal holdings of Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details.
- Share Price: 1,620.8735 pence per Ordinary Share.
- Transaction Type: Increase in interests following the re-investment of the dividend paid on January 9, 2014.
Material Changes
The filing details specific increases in shareholdings for the following individuals:
- Sir Andrew Witty: 3,379 shares.
- Lady C Witty (Connected Person): 1,733 shares.
- Mr I W Whyte (Connected Person): 124 shares.
- Mrs V A Whyte: No change indicated.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory notification compliant with Disclosure and Transparency Rules 3.1.4R(1)(a) and (c).
Investor Verification Points
- Confirm the dividend reinvestment mechanism and its impact on total share count for executive directors.
- Verify the share price of 1,620.8735 pence against market data for January 9, 2014.
- Review the full list of connected persons to ensure all related party transactions are accounted for.